NanoViricides Inc. (NNVC)

[Rawnoc]

Seymour email May 2012:

Now that we're satisfied with the results from the multiple data sets for oral FluCide against the two most common influenza viruses, we can prepare more oral FluCide for the toxicology studies and at the same time, build the pilot manufacturing facility. Both events should conclude simultaneously and once three separate batches are made and tested from that pilot plant, submission to the Australian regulatory authorities can occur. How long from submission to approval can't be known with any certainty until we get to that point. It's generally not a very long time


We've been quoted 2 weeks to complete Phase I safety studies and 4-6 weeks for Phase IIa viral challenge studies


In Phase I, 25 healthy volunteers are given increasing doses of the drug and in Phase IIa, 25 healthy volunteers are infected with the seasonal flu virus, isolated and when they become ill, treated. One can only imagine what the stock will do at that point.


Sincerely,




EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics

http://www.nanoviricides.com
[e-mail]